Related Experiment Video

Updated: May 5, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

36.1K

Catechol-O-methyltransferase Val158Met polymorphism (rs4680) is associated with pain in multiple sclerosis

César Fernández-de-las-Peñas1, Silvia Ambite-Quesada, Rosa Ortíz-Gutiérrez

  • 1Department of Physical Therapy, Occupational Therapy, Rehabilitation and Physical Medicine, Universidad Rey Juan Carlos, Alcorcón, Madrid, Spain; Esthesiology Laboratory, Universidad Rey Juan Carlos, Alcorcón, Madrid, Spain.

The Journal of Pain
|December 3, 2013
PubMed
Abstract

Insights

The rs4680 Val158Met polymorphism, specifically the Met/Met genotype, is linked to a higher prevalence of pain in multiple sclerosis (MS) patients. This genetic factor may increase susceptibility to pain in MS but not MS itself.

Area of Science:

  • Neurogenetics
  • Pain Research
  • Multiple Sclerosis (MS) Genetics

Background:

  • The rs4680 Val158Met polymorphism is associated with pain perception.
  • The role of this polymorphism in pain susceptibility in multiple sclerosis (MS) remains uninvestigated.

Purpose of the Study:

  • To investigate the relationship between the rs4680 Val158Met polymorphism and the presence of pain in individuals with MS.
  • To determine if this polymorphism influences pain susceptibility in MS patients.

Main Methods:

  • Genotyping of the rs4680 Val158Met polymorphism using polymerase chain reactions in 108 MS patients and 108 matched controls.
  • Analysis of genotype frequencies and allele distributions.
  • Comparison of genotype prevalence between MS patients with and without pain, and healthy controls.

Main Results:

  • No significant difference in rs4680 Val158Met genotype distribution was found between MS patients and healthy controls.
  • A significant difference in genotype prevalence was observed between MS patients with and without pain (P = .046).
  • MS patients experiencing pain showed a higher prevalence of the Met/Met genotype compared to those without pain and healthy controls.

Conclusions:

  • The Met allele of the rs4680 Val158Met polymorphism may be a risk factor for developing pain in MS.
  • This polymorphism is not associated with MS predisposition itself.
  • Further evidence suggests potential genetic factors influencing pain development in MS patients.
Keywords:
Catechol-O-methyltransferase genemultiple sclerosispainpolymorphism

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

11.7K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
31
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
160
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
14.8K